Nrx pharmaceuticals reports minutes of recent u.s. food and drug administration (fda) meeting on the development of nrx-101 to treat severe bipolar depression in patients with suicidality

Fda discussed a broader indication of "treatment of recently acutely suicidal patients" with bipolar depression. this broader indication does not require ketamine as the only stabilization agent.

NRXP Ratings Summary

NRXP Quant Ranking